Robeco Institutional Asset Management B.V. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 36.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,647 shares of the biotechnology company's stock after selling 963 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in United Therapeutics were worth $345,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Charter Oak Capital Management LLC bought a new position in shares of United Therapeutics in the second quarter worth $25,000. Cullen Frost Bankers Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at $26,000. Ronald Blue Trust Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at $28,000. Hallmark Capital Management Inc. acquired a new stake in shares of United Therapeutics in the second quarter valued at $33,000. Finally, Neo Ivy Capital Management acquired a new stake in shares of United Therapeutics in the second quarter valued at $48,000. Institutional investors own 95.63% of the company's stock.

United Therapeutics Stock Down 0.2 %

Shares of United Therapeutics stock opened at $261.04 on Friday. The stock has a 50-day moving average price of $271.03 and a 200 day moving average price of $240.39. The company has a market cap of $11.90 billion, a P/E ratio of 17.76, a P/E/G ratio of 1.54 and a beta of 0.62. The company has a current ratio of 9.68, a quick ratio of 9.39 and a debt-to-equity ratio of 0.18. United Therapeutics Co. has a 1 year low of $158.38 and a 1 year high of $283.09.

Analyst Ratings Changes

Several analysts have recently weighed in on UTHR shares. Bank of America restated an "underperform" rating on shares of United Therapeutics in a report on Tuesday, September 20th. Oppenheimer upped their price objective on United Therapeutics from $325.00 to $375.00 and gave the company an "outperform" rating in a report on Thursday, November 3rd. Wedbush upped their price objective on United Therapeutics from $250.00 to $305.00 in a report on Thursday, November 3rd. Argus upped their price objective on United Therapeutics from $250.00 to $300.00 and gave the company a "buy" rating in a report on Wednesday. Finally, HC Wainwright upped their target price on United Therapeutics from $255.00 to $300.00 and gave the company a "buy" rating in a report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $283.64.

Insider Buying and Selling

In other United Therapeutics news, Director Nilda Mesa sold 290 shares of the company's stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $268.57, for a total value of $77,885.30. Following the transaction, the director now directly owns 6,180 shares of the company's stock, valued at approximately $1,659,762.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other United Therapeutics news, Director Nilda Mesa sold 290 shares of the company's stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $268.57, for a total value of $77,885.30. Following the transaction, the director now directly owns 6,180 shares of the company's stock, valued at approximately $1,659,762.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 6,000 shares of the company's stock in a transaction dated Thursday, October 20th. The stock was sold at an average price of $216.68, for a total value of $1,300,080.00. Following the completion of the transaction, the executive vice president now directly owns 36,397 shares in the company, valued at $7,886,501.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 183,390 shares of company stock valued at $48,335,135. Corporate insiders own 12.40% of the company's stock.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

• Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
• MarketBeat: Week in Review 01/09-01/13
• JPMorgan Chase Falls As Banks Brace For Recession
• Why is the Bed Bath & Beyond Stock Price up 261%?
• Roku Stock Price is Trending, Here's Why
• Carvana Stock Rally, Here's What You Need to Know

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.